Clinical Trials

172 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

372 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06966453 2026-04-21

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

100 enrolled

Breast Neoplasms

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

37 enrolled

HER2-low Breast Cancer

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

555 enrolled

Stomach Neoplasms

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Neoplasms

NCT05851677 2025-09-17

Disitamab Vedotin (RC48-ADC) in Breast Cancer

Recruiting

45 enrolled

Breast Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

74 enrolled

Breast Neoplasms

NCT06540729 2025-07-08

DAB

39 enrolled

Ovarian Neoplasms

NCT06558682 2025-04-01

Neoadjuvant Therapy in Cervical Cancer

Phase NA Recruiting

48 enrolled

Uterine Cervical Neoplasms

NCT06642545 2025-02-17

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Breast Neoplasms

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

110 enrolled

Stomach Neoplasms

NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

58 enrolled

Thoracic

Lung Neoplasms

NCT06663007 2024-10-29

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

72 enrolled

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

5 enrolled

Ovarian Cancer Recurrent

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

90 enrolled

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT06560528 2024-08-19

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Stomach Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06378242 2024-07-11

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

24 enrolled

High-risk Non-muscle Invasive Bladder Cancer

NCT06227156 2024-05-23

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Castration-resistant Prostate Cancer

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

79 enrolled

Breast Neoplasms

NCT06221748 2024-04-03

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Phase 2/3 Recruiting

90 enrolled

Stomach Neoplasms

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

116 enrolled

Uterine Cervical Neoplasms

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

312 enrolled

HER2-positive Metastatic Breast Cancer

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

452 enrolled

Carcinoma, Transitional Cell

NCT06155383 2023-12-14

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

90 enrolled

Stomach Neoplasms

NCT05940896 2023-11-27

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Phase 1 Recruiting

24 enrolled

Other solid neoplasm

Solid Tumor

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05904964 2023-06-22

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

288 enrolled